"Additionally, Dr Byon served as Senior Medical Director at Juno Therapeutics, where as the
Global Clinical Development Lead he was instrumental in the clinical development of
orvacabtagene autoleucel (orva-cel/JCARH125) for relapsed/refractory multiple
myeloma and other novel CAR T-cell targets"
Excellent appointment team management, and yes he has runs on the board!
Juno Therapeutics was taken over for $6B.
CLL/SLL: Efficacy of CD19-Directed CAR T-Cell Therapy in Relapsed or Refractory Disease
Study details in the Ascot Post on 29 August 2023, for article reported in The Lancet.
https://ascopost.com/news/august-2023/cllsll-efficacy-of-cd19-directed-car-t-cell-therapy-in-relapsed-or-refractory-disease/?utm_source=pushly
Regards.
"Additionally, Dr Byon served as Senior Medical Director at Juno...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |